Pharmaceutical Report Library l Report Store l Pharma Intelligence

Blood Gas Monitoring Systems

Arterial blood gases are the most commonly ordered test in critical care settings such as ICUs and ORs.Tests with rapid turnaround times, such as POC tests, are largely replacing the slower laboratory test market.

March 28, 2019

Find out more

Multiple Sclerosis KOL Insight Interview

$599.00

Multiple Sclerosis KOL Insight Interview

October 28, 2014

Find out more

ND0612

The ND0612 (Mitsubishi Tanabe) product line comprises two subcutaneous, continuously delivered carbidopa/levodopa liquid formulations: the lower-dose ND0612L, and the higher-dose ND0612H.

June 21, 2018

Find out more

Market Spotlight: Insomnia

$1,318.00

This Market Spotlight report covers the insomnia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming events and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

March 17, 2022

Find out more

Celgene

$3,000.00

PharmaVitae explores Celgene’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.

October 8, 2018

Find out more

Travivo

Travivo (gepirone ER; GlaxoSmithKline/Mission Pharmacal) is a pyridinyl piperazine 5-HT1A receptor agonist, and is distinct from available therapies as it is not a reuptake inhibitor and has no material norepinephrine or dopamine activity. Unlike tricyclic antidepressants or selective serotonin reuptake inhibitors that act on most or all of the 5-HT subtypes in the brain and may have several adverse effects, trials for Travivo have shown benign adverse effects without significant dopaminergic effects.

March 29, 2019

Find out more

Glyxambi

Glyxambi is a fixed-dose combination of sodium-glucose cotransporter-2 inhibitor Jardiance (empagliflozin; Boehringer Ingelheim/Eli Lilly) and dipeptidyl peptidase-IV inhibitor Tradjenta.

November 7, 2017

Find out more

Adynovate

Adynovate is a long-acting PEGylated recombinant factor VIII (rfVIII) therapy developed by Baxalta and Nektar Therapeutics as a follow-on to Advate (rfVIII; Shire).

May 4, 2018

Find out more

LixiLan

LixiLan is a once-daily, injectable combination product comprising a fixed ration of Sanofi’s long-lasting basal insulin, Lantus, and glucagon-like peptide-1 (GLP-1) receptor agonist, Lyxumia (lixisenatide).

June 23, 2016

Find out more

U.S. Markets for Compression Therapy and Pressure Reduction and Relief Products Used for Wound Management

$3,750.00

The scope of this report includes compression therapy products (e.g., compression bandages, compression stockings, and pneumatic compression devices) and pressure reduction and relief products (e.g., specialty/integrated beds, mattress replacements, and mattress overlays).

April 1, 2013

Find out more

Ultibro

Ultibro’s (indacaterol/glycopyrrolate bromide; Novartis/Pfizer) extensive clinical trial program for

chronic obstructive pulmonary disease (COPD) and its first-in-class status in Japan and select EU

markets boost its overall clinical and commercial attractiveness.

April 11, 2016

Find out more

Japan Pharma Outlook 2027

$3,000.00

PharmaVitae explores and visualizes market dynamics in the Japan Pharma peer set out to 2027* through analysis and in-house sales forecasts for more than 320 products.

July 2, 2018

Find out more

Digital Pharma: Are We Nearly There?

$2,995.00

Digital’s potential to transform every aspect of the pharmaceutical value chain, from discovery to commercial, is widely documented.

August 14, 2018

Find out more

U.S. Markets for Orthopedic Biomaterials for Viscosupplementation and Cartilage, Ligament/Tendon, and Meniscal Repair and Regeneration

$3,750.00

The United States (U.S.) market for orthopedic biomaterials, as covered by the scope of this report, comprises bioresorbable fixation devices, visco supplementation products, cartilage repair and regeneration technologies.

July 1, 2013

Find out more

Tenofovir alafenamide fumarate

TAF is a prodrug form of tenofovir, the active ingredient in Viread. Tenofovir mimics the natural
substrate of reverse transcriptase and is incorporated into nascent viral DNA strands during
replication. Once incorporated, tenofovir acts as a chain terminator and prevents further replication of
the viral genome (FDA.gov, 2013).

May 14, 2015

Find out more

Dexferrum

Dexferrum (iron dextran; Luitpold Pharmaceuticals) is an intravenous (IV) iron maintenance treatment used to help elevate hemoglobin levels in patients with anemia in chronic kidney disease (CKD).

January 11, 2018

Find out more

Zybrestat

Zybrestat (fosbretabulin tromethamine; Mateon Therapeutics) is a water-soluble prodrug of cis-combretastatin A4, originally isolated from the African bush willow (Combretum caffrum).

August 17, 2017

Find out more

ALKS 3831

ALKS 3831 is an orally available, fixed-dose combination of samidorphan (ALKS 33) and olanzapine being developed by Alkermes.

April 9, 2018

Find out more

Aubagio

Aubagio is the major active metabolite of Arava (leflunomide), Sanofi’s oral treatment for rheumatoid arthritis, and is a dihydroorotate dehydrogenase (DHODH) inhibitor.

November 24, 2017

Find out more

Cinqair

Cinqair (reslizumab; Teva) is a humanized monoclonal antibody which targets interleukin (IL)-5. IL-5 has been shown to play a key role in the maturation, growth, and chemotaxis of eosinophils, which are inflammatory white blood cells implicated in a number of allergic diseases, including asthma.

February 16, 2018

Find out more

Firmagon

Firmagon (degarelix; Ferring/Astellas) is a gonadotropin-releasing hormone (GnRH) receptor antagonist that directly binds to GnRH receptors in the anterior pituitary gland, rapidly reducing the circulating gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and leading to the rapid suppression of testosterone in men.

January 18, 2018

Find out more

DCVax-L

DCVax-L (Northwest Biotherapeutics) is a dendritic cell vaccine in development for the treatment of glioblastoma multiforme (GBM). It is a personalized immunotherapy that utilizes patients’ own dendritic cells to stimulate…

April 13, 2016

Find out more

Dyslipidemia KOL Insight Interview #1

$599.00

Discusses usage of PCSK9 and CETP inhibitors in various scenarios based on outcomes data

July 25, 2014

Find out more

Taltz

Taltz (ixekizumab; Eli Lilly/Torii Pharmaceutical) is a humanized, immunoglobulin G subclass 4 monoclonal antibody that neutralizes interleukin-17.

May 18, 2018

Find out more

Disease Analysis: Pulmonary Hypertension

Pulmonary hypertension (PH) is a life-threatening and often fatal disease characterized by abnormal vascular proliferation and remodeling of the small pulmonary arteries and arterioles, vasoconstriction, and in situ thrombosis. This leads to a progressive increase in pulmonary vascular resistance (PVR) and, ultimately, the development of right ventricular (RV) dysfunction. Cornerstone histopathological features of the PH vasculopathy include intimal thickening, concentric hypertrophy, and perivascular fibrosis of distal pulmonary arterioles.

May 20, 2022

Find out more

Betaseron

Betaseron was the first drug to reach the market that modifies the course of multiple sclerosis (MS), after launching in the US in 1994 and the EU in 1996 (where it is marketed as Betaferon).

November 24, 2017

Find out more

Abuse-Deterrent Opioids Survey KOL Interview

$599.00

Biomedtracker performed a 5-question survey of 30 United States primary care physicians who currently treat patients with chronic pain and prescribe opioids to at least some of their patients with chronic pain to gauge current and future use of abuse-deterrent opioids to treat chronic pain.

March 9, 2017

Find out more

Daromun

Daromun (Philogen) is a combination of Darleukin, a human vascular targeting monoclonal antibody (L19) fused to interleukin-2 (IL-2), and Fibromun, the L19 antibody linked to tumor necrosis factor (TNF). Both IL-2 and TNF are cytokines, key signaling molecules that are involved with the coordination of immunity.

May 23, 2018

Find out more

Cemiplimab

Cemiplimab (Regeneron/Sanofi) is a programmed death-1 (PD-1)-targeted monoclonal antibody

August 30, 2018

Find out more

2014 October Dermatology Survey

$599.00

We performed a 5-question survey of 21 dermatologists to gauge usage of drugs and devices for the treatment of common dermatological conditions and for aesthetic procedures.

October 30, 2014

Find out more

Seviprotimut-L

Seviprotimut-L (Polynoma/CK Life Sciences) is a polyvalent, shed-antigen vaccine in development for the adjuvant treatment of Stage IIb–III melanoma patients. Seviprotimut-L contains a combination of antigens from three proprietary melanoma cell lines, and is intended to stimulate the body’s immune system to fight cancer.

May 23, 2018

Find out more

Mekinist

Mekinist (trametinib; Novartis/Japan Tobacco) is a selective allosteric inhibitor of the MEK1 and MEK2 enzymes in the mitogen-activated protein kinase (MAPK) pathway.

August 30, 2018

Find out more

Alunbrig

Alunbrig (brigatinib; Takeda) is a dual anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.

September 8, 2018

Find out more

Angiomax

Angiomax is a direct thrombin inhibitor which prevents the formation of fibrin from fibrinogen and the activation of coagulation factor XII.

April 14, 2016

Find out more

Ulcerative Colitis (UC) KOL Interview – UK

$599.00

A UK expert in the ulcerative colitis (UC) field dives into the treatment algorithm, critical unmet needs, and pipeline drugs, such as the Janus kinase inhibitors and sphingosine 1-phosphate (S1P) modulators.

March 1, 2021

Find out more

U.S. Markets for Interventional Cardiology Products, April 2016

$4,750.00

In the United States (U.S.), approximately 85.6 million adults have at least one type of cardiovascular disease (CVD), a broad group of disorders that affect the heart and circulatory system. Cardiovascular disease in all its forms accounts for more deaths than any other major cause in the U.S.

April 1, 2016

Find out more

Zontivity

Zontivity (vorapaxar; Merck & Co) gained US and EU approval for the reduction of thromboembolic

events in secondary-prevention patients with a history of myocardial infarction (MI).

April 14, 2016

Find out more

Onfi

Onfi is a 1,5-benzodiazepine that acts by potentiating gamma-aminobutyric acid (GABA)ergic transmission through binding at the GABA[A] receptor.

May 23, 2017

Find out more

Eloctate

Eloctate (Sanofi/Bioverativ) is a fusion protein consisting of a B-domain deleted factor VIII (fVIII) protein fused to the dimeric human Fc region of immunoglobulin G-1.

May 4, 2018

Find out more

Point of Care Diagnostics

$4,750.00

Point of care in vitro diagnostics is being applied to an increasingly wide range of applications in infectious disease, cardiovascular, respiratory, and metabolic disease diagnosis and screening. The market is undergoing rapid expansion, primarily due to the demand for COVID-19 testing; however, other product segments will also contribute to market growth during the forecast period.

June 28, 2021

Find out more

Beyond-the-Pill Services and Solutions: Pharma’s Next Frontier?

$2,995.00

Payers and governments are striving toward cost-effective treatment outcomes and more efficient care, and waves of new digital health technologies are offering patients unprecedented opportunities to be more engaged in their own health management.

November 2, 2016

Find out more

Chronic Lymphocytic Leukemia (CLL)

The CLL treatment paradigm has changed significantly over the past five years, with targeted therapies such as Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors displacing chemotherapy-based treatments for most patients who have CLL.

March 21, 2022

Find out more

Market Spotlight: Cold Agglutinin Disease

$1,318.00

Cold agglutinin disease (CAD) is a clonal B-cell lymphoproliferative disorder and a rare subgroup of autoimmune hemolytic anemia (AIHA). CAD accounts for 15–25% of AIHA and affects mainly middle aged or older individuals. The disease is characterized by the production of autoantibodies by bone marrow-derived clonal B cells which attach to erythrocytes when exposed to cold temperatures (0–4°C), causing agglutination and eventual immune-mediated hemolysis.

February 28, 2022

Find out more

Sorilux

Following its 2010 launch, Sorilux (calcipotriene; Stiefel/GlaxoSmithKline) has experienced slow

uptake in the psoriasis market, despite having the financial support of GlaxoSmithKline. This comes as

no surprise as the US psoriasis market is saturated with several types of established calcipotriene

formulations, limiting Sorilux’s uptake.

August 26, 2016

Find out more

Chronic Myeloid Leukemia (CML) KOL Interview – US, Midwest

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for chronic myeloid leukemia. Disease stratifications by phase, as well as unmet needs, are also discussed. Key pipeline assets highlighted include asciminib, SCO-088, and ASTX030.

August 5, 2021

Find out more

Report library

Blood Gas Monitoring Systems

Multiple Sclerosis KOL Insight Interview

ND0612

Market Spotlight: Insomnia

Celgene

Travivo

Glyxambi

Adynovate

LixiLan

U.S. Markets for Compression Therapy and Pressure Reduction and Relief Products Used for Wound Management

Ultibro

Japan Pharma Outlook 2027

Digital Pharma: Are We Nearly There?

U.S. Markets for Orthopedic Biomaterials for Viscosupplementation and Cartilage, Ligament/Tendon, and Meniscal Repair and Regeneration

Tenofovir alafenamide fumarate

Dexferrum

Zybrestat

ALKS 3831

Aubagio

Cinqair

Firmagon

DCVax-L

Dyslipidemia KOL Insight Interview #1

Taltz

Disease Analysis: Pulmonary Hypertension

Betaseron

Abuse-Deterrent Opioids Survey KOL Interview

Daromun

Cemiplimab

2014 October Dermatology Survey

Seviprotimut-L

Mekinist

Alunbrig

Angiomax

Ulcerative Colitis (UC) KOL Interview – UK

U.S. Markets for Interventional Cardiology Products, April 2016

Zontivity

Onfi

Eloctate

Point of Care Diagnostics

Beyond-the-Pill Services and Solutions: Pharma’s Next Frontier?

Chronic Lymphocytic Leukemia (CLL)

Market Spotlight: Cold Agglutinin Disease

Sorilux

Chronic Myeloid Leukemia (CML) KOL Interview – US, Midwest